drugset / Trial / NCT01787539

The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer

NCT01787539

RandomizedParallel-groupOpen-labelTreatment

Summary

Taking into account the substantial doubts concerning the potential benefit of postoperative part in the perioperative chemotherapy regimen we designed a study assessing value of this approach in gastric cancer. To improve compliance with a protocol regimen of this aggressive combined therapy we replaced tested in the MAGIC trial ECF regimen with more effective and better tolerable EOX chemotherapy regimen. The value of postoperative three-cycle EOX regimen will be tested in patients with locoregionally advanced gastric cancer with positive pathological response to preoperative three-cycle EOX chemotherapy regimen. The patients will be randomized to the postoperative chemotherapy or to the follow-up arm.

Timeline

Start
2013-02
Primary completion
2017-02
Completion
2022-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 625 mg/m2 Oral
Subject Epirubicin Small molecule 50 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 130 mg/m2 Intravenous

Indications